CIRCULATING FABP4 AND FABP5 LEVELS IN OSA SEVERITY AND TREATMENT
Circulating FABP4 and FABP5 Levels Are Differently Linked to OSA Severity and Treatment
Raquel Català, MD1,2; Anna Cabré, PhD2,3; Salvador Hernández-Flix, MD1,2; Raimón Ferré, MD, PhD2,3; Sandra Sangenís, MD1,2; Núria Plana, MD, PhD2,3; Anna Texidó, MD, PhD1,2; Lluís Masana, MD, PhD2,3
1Sleep Disorders Unit, Respiratory Department, Reus, Spain; 2“Sant Joan” University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain; 3Research Unit on Lipids and Atherosclerosis, Vascular Medicine and Metabolism Unit, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Reus, Spain
To evaluate circulating adipocyte and epidermal fatty acid-binding protein (FABP4 and FABP5) concentrations in patients with obstructive sleep apnea (OSA), as well as the effects of continuous positive airway pressure (CPAP) treatment.
Our cross-sectional study included 125 patients. After polysomnography, 58 participants met the criteria for CPAP treatment and were included in a closed cohort study of 8 weeks of CPAP treatment. General anthropometric and biochemical data and circulating FABP4 and FABP5 levels were determined in all patients at baseline and after CPAP treatment in those receiving this therapy.
Results Circulating FABP4 but not FABP5 levels were higher in patients with OSA (P = 0.003). FABP4 but not FABP5 values were associated with parameters of OSA severity independently of age, gender, adiposity and insulin resistance (P < 0.05). FABP4 but not FABP5 concentrations were determinants of OSA presence (OR: 1.11, P = 0.010) and severity (OR: 1.06, P = 0.020). After CPAP treatment, FABP4 levels decreased in the more severe patients (P = 0.019), while FABP5 levels increased in all patients (P < 0.001).
Conclusions FABP4 is directly associated with obstructive sleep apnea severity and did not change with continuous positive airway pressure treatment, while FABP5 was not associated with obstructive sleep apnea severity and increased with continuous positive airway pressure treatment. FABP4 and FABP5 have different associations with obstructive sleep apnea. FABP4 but not FABP5 could be considered a marker of metabolic alterations in obstructive sleep apnea patients.
Català R; Cabré A; Hernández-Flix S; Ferré R; Sangenís S; Plana N; Texidó A; Masana L. Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment. SLEEP 2013;36(12):1831-1837.